- Zydena is the 4th therapeutic oral new drug for erectile dysfunction in the world. Zydena, which is new drug for ED, induces strong erection by selective inhibition of cGMP-specific PDE5 which is mainly presented in corpora cavernosa.
- 88.5% of the ED subjects shows improvement of erectile function. In phase III clinical trial at 13 institutions including Seoul National University Hospital for 6 months with 270 ED subjects, 81.5%(zydena 100mg)/88.5%(zydena 200mg) of subjects showed improved erectile function in Global Assessment Question.
- Zydena has adequate duration (8-12 hours) of drug action. In the result of clinical pharmacokinetics, Tmax of Zydena is 1 hour and T1/2 is 10-12 hours. Zydena shows high intercourse success rate even at post 8-12 hours from administration of Zydena 100mg in phase III clinical trial.
- Its good tolerance and safety were confirmed in phase I,II and III clinical trials. the major adverse drug reactions were flushing, nasal congestion, ocular hyperaemia, headache and dyspepsia, and most of these reactions, which were reported during clinical trials, were slight and voluntarily gone with no therapy. Thus, it is confirmed that Zydena has good safety and tolerance.
- Zydena has no inhibitory action to PDE 11 and no report has been made about myagia,back pain and testis toxicity. Zydena has no inhibitory action to PDE11, which is heteoenzyme of PDE, and no report has been made about myalgia, back pain and testis toxicity during clinical trials.
